Discover the Latest in Biomedical Research Innovation

Your drug works in wild-type mice and not in the knockout, so the effect depends on the gene. That conclusion does not follow, and in one major review of top journals, half the papers that needed the right test got it wrong. This two-way ANOVA interaction SOP runs the correct analysis in GraphPad Prism, from data entry to a reportable result, with a worked example in which the naive reading and the right answer disagree.

Reviewers examining 100 clinical papers found 65% needed revisions just to explain what their statistical tests were for, and 64% had omitted effect sizes entirely. Statistical reporting problems are rarely about running the wrong analysis; they're about not writing down enough for a reader to judge it. Here's what belongs in the section, built on the SAMPL guidelines: seven things to state in your methods, the results formats that draw fewest queries, and a template you can

Run an ANCOVA and a multiple regression on the same data, specified equivalently, and you get the same F, the same p, and the same coefficients. They are one model with two traditions, and dummy coding is the bridge. So the real question isn't which is correct but which framing makes your result clearest. This piece covers why they're equivalent, what genuinely differs, and how to describe your model so reviewers from either tradition can follow it.

Hunted through Prism's Analyze menu for ANCOVA? It isn't there, and GraphPad's own FAQ confirms they've never shipped one. Prism can still do it, through two documented routes most users never find: the simple-linear-regression slopes test for the parallel-slopes assumption, and multiple regression with dummy-coded groups for the adjusted comparison. Here are both step by step, plus an honest comparison with describing the same analysis in plain language instead.

Your treated and control wells started at different confluence, so comparing endpoints with a plain ANOVA measures your treatment effect plus the head start. ANCOVA fixes that by adjusting for a continuous covariate, and usually buys power too. This step-by-step ANCOVA protocol runs 24 numbered steps from covariate choice through reporting, with the assumption checks in the order they need to happen, including the parallel-slopes test most people skip.

An audit of 200 published animal studies found only 22% had replicated the right thing, and 46% counted repeated measurements of one biological unit as independent samples. That error, pseudoreplication, inflates your n, shrinks your error bars, and manufactures significance that won't replicate. Here's what separates technical vs biological replicates, why the mistake inflates false positives, and what actually counts as a biological replicate in cell culture.

Sophie 4.5 is live. It keeps everything that made 4.0 work and sharpens what matters: the core chat is ~40% more intelligent at the same speed, and the Regulatory Architect is 3x faster, ~25% smarter, and now wired directly into the CFR database for more accurate device classification. The Visualizer and Analytics engines get intelligence and speed bumps, and a wave of UI/UX updates came straight from how people used 4.0. Here's everything new in CLYTE's Sophie 4.5.

You asked to get CytCut onto your bench now instead of waiting, so here it is. CytCut 3.5 is available for immediate order at $36, in 24- and 48-well, the same wound healing assay tool that turns minutes of pipette scratching into seconds of consistent, reproducible wounds. It's UV- and alcohol-sanitizable with a 3–6 month working life. The autoclavable CytCut 4.0 is still on track for end of September at $99 pre-order. Order 3.5 with code cytcut352673 for $15 off through Jul

Research innovation is an essential driver of progress in various fields, from healthcare to technology. It can shape how we understand our world and create solutions for its challenges. As we delve into the emerging trends in this exciting landscape, we find new technologies and methodologies that promise to transform traditional research paradigms.

Over 50% of biomedical research is irreproducible, costing $28B+ yearly. Learn the causes, impact, and solutions to fix science!